AQR Capital Management LLC Has $71.91 Million Stock Holdings in Organon & Co. (NYSE:OGN)

AQR Capital Management LLC raised its position in Organon & Co. (NYSE:OGN) by 39.8% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 3,473,655 shares of the company’s stock after acquiring an additional 988,336 shares during the period. AQR Capital Management LLC owned about 1.35% of Organon & Co. worth $71,905,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Organon & Co. in the fourth quarter worth $26,321,000. Franklin Resources Inc. lifted its position in Organon & Co. by 55.7% during the 4th quarter. Franklin Resources Inc. now owns 180,815 shares of the company’s stock worth $2,607,000 after buying an additional 64,683 shares in the last quarter. Advisory Services Network LLC boosted its stake in shares of Organon & Co. by 4.0% during the 4th quarter. Advisory Services Network LLC now owns 57,962 shares of the company’s stock worth $836,000 after buying an additional 2,204 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Organon & Co. by 334.5% in the 4th quarter. Parallel Advisors LLC now owns 14,699 shares of the company’s stock valued at $212,000 after acquiring an additional 11,316 shares in the last quarter. Finally, United Services Automobile Association acquired a new stake in shares of Organon & Co. in the fourth quarter valued at about $232,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Organon & Co. stock opened at $19.18 on Friday. The stock has a 50-day simple moving average of $20.84 and a 200 day simple moving average of $20.13. The stock has a market capitalization of $4.94 billion, a P/E ratio of 4.69, a PEG ratio of 0.87 and a beta of 0.85. The company has a debt-to-equity ratio of 60.05, a quick ratio of 1.17 and a current ratio of 1.64. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $23.10.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. The company had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The business’s revenue was down .1% on a year-over-year basis. During the same period last year, the firm posted $1.31 earnings per share. Analysts expect that Organon & Co. will post 4.14 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.12 dividend on an annualized basis and a yield of 5.84%. Organon & Co.’s dividend payout ratio (DPR) is 27.38%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on OGN shares. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and raised their target price for the company from $18.00 to $20.00 in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Organon & Co. has an average rating of “Hold” and an average target price of $21.00.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.